Evidence map›Paper›PMID 36153998›Full record

ArticleJournal of medicinal chemistry2022

Targeting the Phosphatidylserine-Immune Checkpoint with a Small-Molecule Maytansinoid Conjugate.

Chen-Fu Lo, Tai-Yu Chiu, Yu-Tzu Liu, Pei-Yun Pan, Kuan-Liang Liu, Chia-Yu Hsu, Ming-Yu Fang, Yu-Chen Huang, Teng-Kuang Yeh, Tsu-An Hsu and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Chen-Fu LoInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli35053, Taiwan, ROC.
Tai-Yu ChiuInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli35053, Taiwan, ROC.
Yu-Tzu LiuInstitute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli35053, Taiwan, ROC.
Pei-Yun PanInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli35053, Taiwan, ROC.
Kuan-Liang LiuInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli35053, Taiwan, ROC.
Chia-Yu HsuInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli35053, Taiwan, ROC.
Ming-Yu FangInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli35053, Taiwan, ROC.
Yu-Chen HuangInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli35053, Taiwan, ROC.
Teng-Kuang YehInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli35053, Taiwan, ROC.
Tsu-An HsuInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli35053, Taiwan, ROC.
Chiung-Tong ChenInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli35053, Taiwan, ROC.
Li-Rung HuangInstitute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli35053, Taiwan, ROC.
Lun Kelvin TsouInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli35053, Taiwan, ROC.ORCID 0000-0002-1593-5226
National Health Research Institutes · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ligand-targeting drug delivery systems have made significant strides for disease treatments with numerous clinical approvals in this era of precision medicine. Herein, we report a class of small molecule-based immune checkpoint-targeting maytansinoid conjugates. From the ligand targeting ability, pharmacokinetics profiling,

Indexed as

PhosphatidylserinesTriple Negative Breast NeoplasmsHumansLigandsRNA, MessengerSorafenibTumor MicroenvironmentLigandsPhosphatidylserinesRNA, MessengerSorafenib

Identifiers

PMID36153998
PMCPMC9574934
OpenAlexW4297225407

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.